To address this gap, we performed a comprehensive genomic analysis of 362 children (median age 4 years, range 1–17 years; 171 females) with newly diagnosed ETV6::RUNX1-positive B-ALL treated according to the NOPHO ALL2000 (n = 50) or ALL2008 (n = 312) protocols (Figs. 1B and S1A-B). This evidence concerns the gene RUNX1 and acute lymphoblastic leukemia.